



Karyopharm Therapeutics  
Investor Relations Department  
85 Wells Ave, 2nd floor  
Newton, MA 02459  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: KPTI

Last Trade:	11.47
Trade Time:	4:00 PM ET Nov 17, 2017
Change:	0.08  (+0.702%)
Day Range	11.15 - 11.56
52-Week Range	7.48 - 14.63
Volume	89,365

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

### Corporate Profile

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmu... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Nov 13, 2017 [Karyopharm Therapeutics to Present at the Jefferies 2017 London Healthcare Conference](#)
- Nov 3, 2017 [Karyopharm Therapeutics to Participate in the Credit Suisse 26th Annual Healthcare Conference](#)
- Nov 2, 2017 [Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress](#)
- Nov 1, 2017 [Karyopharm to Present Phase 1b/2 STOMP Clinical Data at the American Society of Hematology 2017 Annual Meeting](#)
- Oct 26, 2017 [Karyopharm to Report Third Quarter 2017 Financial Results on November 2, 2017](#)

### Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 16, 2017 [Annual Report \(10-K\)](#)
- Apr 28, 2017 [Proxy Statement \(DEF 14A\)](#)
- Nov 2, 2017 [Quarterly Report \(10-Q\)](#)
- Aug 8, 2017 [Quarterly Report \(10-Q\)](#)
- May 4, 2017 [Quarterly Report \(10-Q\)](#)